This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Cookies Policy.

This page is intended for US healthcare providers only.

This page is intended for US healthcare providers only.

HER2 SHOULD BE USED TO INFORM TREATMENT DECISIONS IN COLORECTAL CANCER1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend testing for HER2 amplification in patients with unresectable or metastatic colorectal cancer2,3

HER2 amplification may be associated with a lower response rate and shorter PFS in patients treated with anti-EGFR therapies.4,5

  • Currently, anti-EGFR agents are a common treatment approach for RAS/BRAF WT mCRC in later lines of therapy1,5
  • However, HER2 amplification may be associated with decreased activity of anti-EGFR therapies in patients with RAS/BRAF WT mCRC4,5

NCCN Guidelines® recommend HER2-targeted therapies as subsequent treatment options in mCRC patients with tumors that have HER2 overexpression.2,3

Learn more about the importance of testing in mCRC.

Testing can help inform your treatment decisions.

List of Labs Testing for HER2 in mCRC

Seagen: Advancing science to transform treatment of HER2+ cancer

EGFR = epidermal growth factor receptor; HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer; NCCN = National Comprehensive Cancer Network® (NCCN®); PFS = progression-free survival; WT = wild type.

References: 1. Raghav KPS. The role of HER2 amplification testing in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2018;16(11):720-722. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed November 7, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed November 7, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24(10):1395-1402. doi:10.1634/theoncologist.2018-0785 5. Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;1-13. doi:10.1200/PO.18.00226

Seagen and are US registered trademarks of Seagen Inc.

© 2022 Seagen Inc., Bothell, WA 98021.
All rights reserved. US-DIS-22-272-MT Produced in USAProduced in USA